Ligand-based NMR spectra demonstrate an additional phytoestrogen binding site for 17β-hydroxysteroid dehydrogenase type 1

Journal of Steroid Biochemistry and Molecular Biology

Volumn 117, Issue 4-5, 2009, Pages 93-98

  Michiels, Paul J A ^a,d   Ludwig, Christian ^a   Stephan, Michel ^b   Fischer, Christina ^f   Möller, Gabriele ^c   Messinger, Josef ^e   van Dongen, Maria ^d   Thole, Hubert ^e   Adamski, Jerzy ^c   Günther, Ulrich L ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b PhosPhoenix SARL   (France)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d Solvay Pharmaceuticals Inc   (Netherlands)

^e Solvay Pharmaceuticals GmbH   (Germany)

^f NONE

Author keywords

17 HSD1 NMR; 17 Hydroxysteroid dehydrogenase type 1; Epitope mapping; Hydroxysteroid dehydrogenase

Indexed keywords

APIGENIN; DIMER; ESTRADIOL; ESTRONE; LUTEOLIN; PHYTOESTROGEN; TESTOSTERONE 17BETA DEHYDROGENASE; TESTOSTERONE 17BETA DEHYDROGENASE 1; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING KINETICS; BINDING SITE; COMPETITIVE INHIBITION; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME STRUCTURE; ENZYME SUBSTRATE COMPLEX; EPITOPE MAPPING; HORMONE INHIBITION; IN VITRO STUDY; LIGAND BINDING; MOLECULAR DOCKING; NUCLEAR MAGNETIC RESONANCE; PH; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

17-HYDROXYSTEROID DEHYDROGENASES; BASE SEQUENCE; BINDING SITES; DNA PRIMERS; HYDROGEN-ION CONCENTRATION; LIGANDS; MODELS, MOLECULAR; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PHYTOESTROGENS;

EID: 70350545710     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2009.07.004     Document Type: Article

References (39)

1. Duncan L.J., and Reed M.J. The role and proposed mechanism by which oestradiol 17β-hydroxysteroid dehydrogenase regulates breast tumour oestrogen concentrations. J. Steroid. Biochem. Mol. Biol. 55 (1995) 565-572
2. 3H]oestradiol in vivo by normal breast and tumour tissue in postmenopausal women. J. Steroid. Biochem. 24 (1986) 361-364
3. Poutanen M., Isomaa V., Lehto V.P., and Vihko R. Immunological analysis of 17β-hydroxysteroid dehydrogenase in benign and malignant human breast tissue. Int. J. Cancer 50 (1992) 386-390
4. Prehn C., Möller G., and Adamski J. Recent advances in 17β-hydroxysteroid dehydrogenases. J. Steroid Biochem. Mol. Biol. 114 (2009) 72-77
5. Allan G.M., Lawrence H.R., Cornet J., Bubert C., Fischer D.S., Vicker N., Smith A., Tutill H.J., Purohit A., Day J.M., Mahon M.F., Reed M.J., and Potter B.V.L. Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17β-hydroxysteroid dehydrogenase type 1. J. Med. Chem. 49 (2006) 1325-1345
6. Bérubé M., and Poirier D. Synthesis of simplified hybrid inhibitors of type 1 17β-hydroxysteroid dehydrogenase via cross-metathesis and Sonogashira coupling reactions. Organic Lett. 6 (2004) 3127-3130
7. Bey E., Marchais-Oberwinkler S., Kruchten P., Frotscher M., Werth R., Oster A., Algül O., Neugebauer A., and Hartmann R.W. Design, synthesis, and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17β-hydroxysteroid dehydrogenase (17β-HSD1) for the treatment of estrogen-dependent diseases. Bioorg. Med. Chem. 16 (2008) 6423-6435
8. Bey E., Marchais-Oberwinkler S., Werth R., Negri M., Al-Soud Y.A., Kruchten P., Oster A., Frotscher M., Birk B., and Hartmann R.W. Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase (17β-HSD1). J. Med. Chem. 51 (2008) 6725-6739
9. Brožič P., Kocbek P., Sova M., Kristl J., Martens S., Adamski J., Gobec S., and Rižner T.L. Flavonoids and cinnamic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 1. Mol. Cell. Endocrinol. 301 (2009) 229-234
10. Fischer D.S., Allan G.M., Bubert C., Vicker N., Smith A., Tutill H.J., Purohit A., Wood L., Packham G., Mahon M.F., Reed M.J., and Potter B.V.L. E-ring modified steroids as novel potent inhibitors of 17β-hydroxysteroid dehydrogenase type 1. J. Med. Chem. 48 (2005) 5749-5770
11. Frotscher M., Ziegler E., Marchais-Oberwinkler S., Kruchten P., Neugebauer A., Fetzer L., Scherer C., Müller-Vieira U., Messinger J., Thole H., and Hartmann R.W. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphtalene and-quinoline derivatives: Potent and selective nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase (17β-HSD1) for the treatment of estrogen-dependent diseases. J. Med. Chem. 51 (2008) 2158-2169
12. Kruchten P., Werth R., Bey E., Oster A., Marchais-Oberwinkler S., Frotscher M., and Hartmann R.W. Selective inhibition of 17β-hydroxysteroid dehydrogenase (17β-HSD1) reduces estrogen responsive cell growth of T47-D breast cancer cells. J. Steroid Biochem. Mol. Biol. 114 (2009) 200-206
13. Lawrence H.R., Vicker N., Allan G.M., Smith A., Mahon M.F., Tutill H.J., Purohit A., Reed M.J., and Potter B.V.L. Novel and potent 17β-hydroxysteroid dehydrogenase type 1 inhibitors. J. Med. Chem. 48 (2005) 2759-2762
14. Marchais-Oberwinkler S., Frotscher M., Ziegler E., Werth R., Kruchten P., Messinger J., Thole H., and Hartmann R.W. Structure-activity study in the class of 6-(3′-hydroxyphenyl)naphtalenes leading to an optimization of a pharmacophore model for 17β-hydroxysteroid dehydrogenase (17β-HSD1) inhibitors. Mol. Cell. Endocrinol. 301 (2009) 205-211
15. Marchais-Oberwinkler S., Kruchten P., Frotscher M., Ziegler E., Neugebauer A., Bhoga U., Bey E., Müller-Vieira U., Messinger J., Thole H., and Hartmann R.W. Substitured 6-phenyl-2-naphtols. Potent and selective non-steroidal inhibitors of 17 β -hydroxysteroid dehydrogenase type 1 (17β-HSD1). J. Med. Chem. 51 (2008) 4685-4698
16. Messinger J., Hirvelä L., Husen B., Kangas L., Koskimies P., Pentikäinen O., Saarenketo P., and Thole H. New inhibitors of 17 β-hydroxysteroid dehydrogenase type 1. Mol. Cell. Endocrin. 248 (2006) 192-198
17. Poirier D. Inhibitors of 17β-hydroxysteroid dehydrogenases. Curr. Med. Chem. 10 (2003) 453-477
18. Poirier D., Boivin R.P., Tremblay M.R., Bérubé M., Qiu W., and Lin S.-X. Estradiol-adenosine hybrid compounds designed to inhibit type 1 17β-hydroxysteroid dehydrogenase. J. Med. Chem. 48 (2005) 8134-8147
19. Poirier D., Chang H.-J., Azzi A., Boivin R.P., and Lin S.-X. Estrone and estradiol C-16 derivatives as inhibitors of type 1 17β-hydroxysteroid dehydrogenase. Mol. Cell. Endocrin. 248 (2006) 236-238
20. Qiu W., Campbell R.L., Gangloff A., Dupuis P., Bolvin R.P., Tremblay M.R., Poirier D., and Lin S.X. A concerted, rational design of type 1 17β-hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrids with high affinity. FASEB J. 16 (2002) 1829-1831
21. N. Vicker, H. Lawrence, G. Allan, C. Bubert, D.S. Fischer, A. Purohit, M. Reed, B. Potter, 17β-Hydroxysteroid dehydrogenase inhibitors, Patent WO/2004/085457 (2003).
22. Vicker N., Lawrence H.R., Allan G.M., Bubert C., Smith A., Tutill H.J., Purohit A., Day J.M., Mahon M.F., Reed M.J., and Potter B.V. Focused libraries of 16-substituted estrone derivatives and modified E-ring steroids: inhibitors of 17β-hydroxysteroid dehydrogenase type 1. Chem. Med. Chem. 1 (2006) 464-481
23. Krazeisen A., Breitling R., Möller G., and Adamski J. Phytoestrogens inhibit human 17β-hydroxysteroid dehydrogenase type 5. Mol. Cell. Endocrinol. 171 (2001) 151-162
24. Deluca D., Krazeisen A., Breitling R., Prehn C., Möller G., and Adamski J. Inhibition of 17β-hydroxysteroid dehydrogenases by phytoestrogens: comparison with other steroid metabolizing enzymes. J. Steroid Biochem. Mol. Biol. 93 (2005) 285-292
25. Azzi A., Rehse P.H., Zhu D.W., Campbell R.L., Labrie F., and Lin S.X. Crystal structure of human estrogenic 17β-hydroxysteroid dehydrogenase complexed with 17β-estradiol. Nat. Struct. Biol. 3 (1996) 665-668
26. + identifies two principal targets for the design of inhibitors. Structure 4 (1996) 905-915
27. +. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 840-845
28. Hoffren A.M., Murray C.M., and Hoffmann R.D. Structure-based focusing using pharmacophores derived from the active site of 17β-hydroxysteroid dehydrogenase. Curr. Pharm. Des. 7 (2001) 547-566
29. Dalvit C., Pevarello P., Tatò M., Veronesi M., Vulpetti A., and Sundström M. Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water. J. Biomol. NMR 18 (2000) 65-68
30. Dalvit C., Fogliatto G., Stewart A., Veronesi M., and Stockman B. WaterLOGSY as a method for primary NMR screening: practical aspects and range of applicability. J. Biomol. NMR 21 (2001) 349-359
31. Ludwig C., Michiels P.J., Wu X., Kavanagh K.L., Pilka E., Jansson A., Oppermann U., and Günther U.L. SALMON: solvent accessibility, ligand binding, and mapping of ligand orientation by NMR spectroscopy. J. Med. Chem. 51 (2008) 1-3
32. Mayer M., and Meyer B. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew. Chem. Int. Ed. 38 (1999) 1784-1788
33. Zhou P., Lugovskoy A.A., and Wagner G. A solubility-enhancement tag (SET) for NMR studies of poorly behaving proteins. J. Biomol. NMR 20 (2001) 11-14
34. Deluca D., Möller G., Rosinus A., Elger W., Hillisch A., and Adamski J. Inhibitory effects of fluorine-substituted estrogens on the activity of 17β-hydroxysteroid dehydrogenases. Mol. Cell. Endocrinol. 248 (2006) 218-224
35. Hwang T., and Shaka A. Water suppression that works. Excitation saculpting arbitrary waveforms and pulsed field gradients. J. Magn. Reson. Ser. A 112 (1995) 275-279
36. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., and Olson A.J. Automated docking using a lamarckian genetic algorithm and empirical binding free energy function. J. Comput. Chem. 19 (1998) 1639-1662
37. + in 17β-hydroxysteroid dehydrogenase. J. Biol. Chem. 273 (1998) 8145-8152
38. Le Bail J.C., Laroche T., Marre-Fournier F., and Habrioux G. Aromatase and 17β-hydroxysteroid dehydrogenase inhibition by flavonoids. Cancer Lett. 133 (1998) 101-106
39. Jin J.Z., and Lin S.X. Human estrogenic 17β-hydroxysteroid dehydrogenase: predominance of estrone reduction and its induction by NADPH. Biochem. Biophys. Res. Commun. 259 (1999) 489-493